Counselors in Marysvale, UT Accepting Medicare
7 Counselors found. Showing 1 - 7
 Kevin Molchan Counselor Medicare: Not Enrolled in Medicare Practice Location: 8500 S Ten Mile Rd, Marysvale, UT 84750 Phone: 435-326-4300 Fax: 435-326-4313 |
Ryan Swalberg Counselor Medicare: Not Enrolled in Medicare Practice Location: 8500 S Ten Mile Rd, Marysvale, UT 84750 Phone: 435-326-4300 Fax: 435-326-4313 |
Ben Lindgren Counselor Medicare: Not Enrolled in Medicare Practice Location: 8510 S Ten Mile Rd, Marysvale, UT 84750 Phone: 435-201-9215 Fax: 435-527-8883 |
 Mandi Molchan Counselor Medicare: Not Enrolled in Medicare Practice Location: 8510 S Ten Mile Rd, Marysvale, UT 84750 Phone: 435-201-9215 Fax: 435-527-8883 |
Darren Swalberg Counselor Medicare: Not Enrolled in Medicare Practice Location: 8500 S Ten Mile Rd, Marysvale, UT 84750 Phone: 435-326-4300 Fax: 435-326-4313 |
Mr. Chris Woods Counselor Medicare: Not Enrolled in Medicare Practice Location: 8510 S Ten Mile Rd, Marysvale, UT 84750 Phone: 435-201-9215 Fax: 435-527-8883 |
Clint Shepherd Counselor Medicare: Not Enrolled in Medicare Practice Location: 8510 S Ten Mile Rd, Marysvale, UT 84750 Phone: 435-201-9215 Fax: 435-527-8883 |
News Archive
Transcend Services enters into a 27 month contract with HealthTrust
TRANSCEND SERVICES, INC. announced today that it has entered into a 27 month contract with HealthTrust Purchasing Group, LP to offer medical transcription and clinical documentation products and services to nearly 1,400 not-for-profit and for-profit acute care facilities and other health-care organizations within the HealthTrust membership.
Protection of upper respiratory tract will require vaccines that mimic natural infection by SARS-CoV-2
Recently, a team of researchers studied the transmission modes of SARS-CoV-2 and the protection against re-infection in ferret models in work published on the preprint server, bioRxiv.
Clinical study shows tolerability and safety of investigational drug in boys with DMD
Patients with Duchenne muscular dystrophy have few treatment options. Medications currently available or in development either target only a subset of DMD patients with a particular genetic mutation or cause significant side effects.
Research could lead to new drugs that combat HIV infection by shutting down the virus's assembly lines
After infecting a susceptible cell, the human immunodeficiency virus hijacks that cell's normal machinery to produce carbon copies of itself. New HIV particles roll off the cellular assembly lines, burst like bubbles out of the cell, and float off to invade other cellular factories.
Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell engaging antibody for the treatment of solid tumors.
› Verified 2 days ago